Supernus Pharmaceuticals Inc.
SUPN | NASDAQ
$43.53
+$0.75 (+1.75%)
Sep 22, 2026, 2:01 PM ET · Market open
# of Analysts
4
Median Price Target
$63
Median Upside
+44.73%
Consensus Rating
Buy
Low Price Target
$40
High Price Target
$65
Price Target Consensus
| Target | Low | Average | Median | High |
|---|---|---|---|---|
| Price | $40 | $57.60 | $63 | $65 |
| Change | -8.11% | +32.32% | +44.73% | +49.32% |
Latest Analyst Ratings
| Rating | Aug 2025 | Sep 2025 | Nov 2025 | Jun 2026 |
|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 |
Buy | 1 | 2 | 0 | 1 |
Hold | 0 | 0 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
All Analyst Ratings
| Date | Analyst Firm | Action | Rating | Price Target | Upside |
|---|---|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald (4.29) | maintain | Buy | $67 | +53.92% |
| Dec 19, 2025 | Stifel (3.86) | maintain | Hold | $55 | +26.35% |
| Oct 23, 2025 | TD Cowen (3.17) | maintain | Buy | $60 | +37.84% |
Pro Membership
Stop Guessing, Start Knowing.
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
Unlimited access
Unlimited access to all data and tools, giving you the edge over everyone else in the market.
Proprietary Stock Rating Score
Evaluate stocks with our proprietary rating score based on fundamentals, economic moat, and sentiment.
Top Wall Street Analyst Ratings
Follow ratings from the best analysts on Wall Street to stay ahead of market moves.
Up to 30 years financial history
We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.
Add to Watchlist
Select watchlists to add or remove SUPN